Dr. Melania Tesio – Oncologia –  Best Researcher Award

Posted on by sciencefatherLeave a Comment on Dr. Melania Tesio – Oncologia –  Best Researcher Award

Dr. Melania Tesio - Oncologia -  Best Researcher Award

INSERM - France

Author Profile 

SCOPUS 

🎓 Early academic pursuits

Melania Tesio embarked on her academic journey with a solid foundation in medical biotechnology, earning her degree with full honors from the university of torino, italy, in 2002. her passion for oncology led her to pursue a doctoral degree, culminating in a ph.d. in human oncology in 2007. her studies were uniquely enriched by a dual affiliation with the university of torino and the weizmann institute of science, israel, where she collaborated on groundbreaking research projects that laid the groundwork for her future contributions to cancer research.

🧪 Professional endeavors

Following her ph.d., Melania transitioned into impactful research roles. from 2007 to 2008, she worked as a postdoctoral researcher at the weizmann institute of science under prof. tsvee lapidot, where she delved into hematopoietic and immune system dynamics. subsequently, she joined the german cancer research center (dkfz) in 2008, collaborating with prof. andreas trumpp until 2014. since 2017, she has been a researcher at inserm, contributing significantly to unit u1111, lyon, france, where she focuses on translational cancer research while balancing her roles during maternity leave and part-time work.

🔬 Contributions and research focus

Melania's research has consistently centered on understanding the molecular mechanisms underpinning cancer, particularly t-cell acute lymphoblastic leukemia (t-all). her studies have uncovered critical insights into metabolic rewiring induced by genetic abnormalities, such as pten loss. she has also contributed to elucidating Oncologia the molecular blueprints of thymopoiesis and enhancer activation in tcr development. her recent work as a senior researcher has focused on the intersection of metabolism and oncogenesis, driving innovative therapeutic strategies for blood cancers.

🏆 Accolades and recognition

Melania’s contributions have been widely recognized in the scientific community. with an h-index of 19 and over 2,800 citations, her work has significantly impacted Oncologia cancer biology. she has been the last and corresponding author on prestigious publications, showcasing her leadership in collaborative research. her groundbreaking findings have been published in high-impact journals like blood advances, leukemia, and j experimental medicine, further establishing her as a thought leader in oncology research.

🌟 Impact and influence

Through her pioneering research, melania has advanced the understanding of key biological pathways in leukemia, offering new avenues for therapeutic Oncologia interventions. her work on age-related clinical features of pten abnormalities in t-all and molecular mechanisms of tcr enhancer activation has provided valuable frameworks for clinical applications. as a mentor, she has inspired the next generation of researchers, fostering a culture of innovation and collaboration.

🌍 Legacy and future contributions

Melania’s legacy is deeply rooted in her commitment to translational oncology, where she bridges the gap between fundamental research and clinical applications. looking ahead, she aims to expand her research into metabolic dependencies in cancer, paving the way for precision medicine approaches. her dedication to unraveling complex biological systems continues to shape the field of cancer research, ensuring lasting contributions to scientific progress and patient care.

Notable Publications 

  • Title: Tell me who you go with and I'll tell you who you are
    Author: M. Tesio
    Journal: HemaSphere, 2024, 8(1), e36
  • Title: Editorial: Tyrosine kinases and phosphatases in T-cell malignancies
    Author: M. Tesio
    Journal: Frontiers in Oncology, 2024, 14, 1372133
  • Title: Sunscreen to Protect the Marrow
    Author: M. Tesio
    Journal: HemaSphere, 2023, 7(9), pp. E941
  • Title: Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
    Author: M. Tesio
    Journal: HemaSphere, 2023, 7(2), pp. E827
  • Title: Reporting From the First EHA Research Conference: Exciting Science With Panoramic Views
    Author: M. Tesio
    Journal: HemaSphere, 2023, 7(1), pp. E816

Prof Dr. Zhen Yang – Oncology and immunity – Young Scientist Award

Posted on by sciencefatherLeave a Comment on Prof Dr. Zhen Yang – Oncology and immunity – Young Scientist Award

Prof Dr. Zhen Yang - Oncology and immunity - Young Scientist Award

Tianjin Union Medical Center of Nankai University - China

Author Profile 

ORCID

Early academic pursuits 🎓

Dr. Zhen Yang embarked on a journey in the medical field with a focus on understanding complex biological systems. With a Doctor of Medicine degree, Zhen cultivated a deep interest in the mechanisms of diseases, particularly malignant tumors. This foundation laid the groundwork for a career dedicated to advancing medical science and improving therapeutic strategies.

Professional endeavors 🏢

Currently, Zhen serves as a postdoctoral research fellow and a distinguished research fellow, overseeing laboratory technicians and guiding research initiatives. Zhen has played a crucial role in leading significant projects, including the National Natural Science Foundation of China and key initiatives from the Tianjin Health and Education Commissions. These positions reflect Zhen's leadership and commitment to fostering innovative research environments.

Contributions and research focus 🔬

Zhen's research primarily centers on immunotherapy for malignant tumors, integrating Chinese and Western medicine approaches. This unique perspective aims to enhance treatment efficacy and patient outcomes. With over ten published papers in prestigious journals, including Oncology and immunity Autophagy, Cancer Letters, and International Journal of Biological Macromolecules, Zhen's work significantly contributes to the scientific understanding of immunotherapeutic strategies and their applications in clinical settings.

Accolades and recognition 🏅

Zhen's contributions to medical research have not gone unnoticed, with recognition from various academic bodies and funding agencies. Leading projects funded by the National Natural Science Foundation of China and receiving support from Tianjin’s health and education sectors Oncology and immunity underscores Zhen's influence and reputation within the scientific community. Zhen’s work has been pivotal in advancing research methodologies and clinical applications in immunotherapy.

Impact and influence 🌍

The impact of Zhen Yang's research extends beyond academic publications, influencing clinical practices and therapeutic strategies for treating malignant tumors. By bridging traditional and modern medicine, Zhen's work fosters a holistic approach to cancer treatment, potentially Oncology and immunity transforming how therapies are designed and implemented. Zhen’s research serves as a valuable resource for other scientists and clinicians in the field.

Legacy and future contributions 🔮

Dr. Zhen Yang's legacy is one of innovation and dedication to improving cancer therapies. As research in immunotherapy continues to evolve, Zhen is poised to make further significant contributions that could redefine treatment paradigms. The integration of traditional and modern practices in Zhen's work promises to open new avenues for research and clinical application, ensuring a lasting impact on future generations of medical professionals and researchers.

Notable Publications

The METTL3/miR-196a Axis Predicts Poor Prognosis in Non-small Cell Lung Cancer  2024

Inflammatory factor TNFα-induced circDMD mediates R-loop formation to promote tumorigenesis 2024

β-Sitosterol Inhibits Tumor Growth and Amplifies Rituximab Sensitivity through Acid 2024

Effects of maternal advanced lipoxidation end products diet on the glycolipid metabolism 2024

EPYC functions as a novel prognostic biomarker for pancreatic cancer 2024

Mr. Anup Kodape – Biological Sciences – Best Researcher Award

Posted on by sciencefatherLeave a Comment on Mr. Anup Kodape – Biological Sciences – Best Researcher Award

Mr. Anup Kodape - Biological Sciences - Best Researcher Award

Academy of Scientific and Innovative Research - India

Author Profile

SCOPUS

ORCID

Early academic pursuits 🎓

Anup Ramdas Kodape’s academic journey began with a B.Sc. in Botany, Zoology, and Chemistry from Gondwana University, Gadchiroli. He further pursued an M.Sc. in Botany from HISLOP College, Nagpur, where he demonstrated a solid understanding of biological sciences. Currently, he is a Ph.D. candidate in Biological Sciences at CSIR-Central Food Technological Research Institute (CSIR-CFTRI), Mysore, under the Academy of Scientific and Innovative Research. His doctoral research focuses on food protectants and infestation control, particularly targeting the mitigation of aflatoxins in groundnut seeds.

Professional endeavors 🏢

Anup’s professional experience includes a diverse range of roles in both research and teaching. As a Senior Research Fellow at CSIR-CFTRI, Mysore, he is working on developing strategies to mitigate aflatoxins in groundnut seeds. His previous roles include Junior Research Fellow positions at both CSIR-CFTRI and CSIR-National Environmental Engineering Research Institute (NEERI). At NEERI, he worked on CO2 sequestration using algal photobioreactors and air pollution reduction. His teaching experience includes serving as an Assistant Professor at HISLOP College, where he conducted lectures and practicals in botany for undergraduate and postgraduate students.

Contributions and research focus 🔬

Anup’s research is primarily focused on food safety and environmental sustainability. His work at CSIR-CFTRI involves identifying fungal flora in groundnut seeds that produce aflatoxins and developing mitigation strategies using natural compounds, biocontrol, and endophytic challenges. His earlier work at CSIR-NEERI involved CO2 sequestration and air pollution management, showcasing his commitment to addressing Biological Sciences environmental issues through innovative approaches. His contributions significantly advance the understanding and management of aflatoxin contamination and environmental pollution.

Accolades and recognition 🏅

Anup has earned recognition for his academic and research achievements. He has qualified the GATE (Life Sciences) conducted by IIT Bombay Biological Sciences and the UGC NET JRF in Environmental Sciences, which highlights his proficiency in the field. His ongoing Ph.D. research is contributing valuable insights into food safety and environmental protection, garnering respect within the scientific community.

Impact and influence 🌍

Anup’s research has a substantial impact on both food safety and environmental sustainability. His work on aflatoxin mitigation is crucial for improving food security and safety, particularly in groundnut production. Additionally, his contributions to CO2 sequestration and air pollution Biological Sciences reduction are important for addressing global environmental challenges. His research influences practices in food technology and environmental engineering, benefiting both scientific and industrial communities.

Legacy and future contributions 🔮

Anup Ramdas Kodape is poised to leave a lasting legacy in the fields of food safety and environmental science. His innovative research on aflatoxin mitigation and environmental sustainability will likely continue to influence these areas significantly. As he advances in his career, his contributions are expected to further enhance food protection strategies and environmental management practices, contributing to global health and sustainability goals.

Notable Publications

Metagenomic insights of fungal diversity of peanuts under storage conditions and mitigation 2024(1)

Assoc Prof Dr. S. Mohsen Asghari – Cancer diagnosis – Best Innovation Award

Posted on by sciencefatherLeave a Comment on Assoc Prof Dr. S. Mohsen Asghari – Cancer diagnosis – Best Innovation Award

Assoc Prof Dr. S. Mohsen Asghari - Cancer diagnosis - Best Innovation Award

University of Tehran - Iran

Professional Profile

ORCID

EARLY ACADEMIC PURSUITS 🎓

S. Mohsen Asghari was born in 1978 and embarked on his academic journey at Gorgan University, Iran, where he earned his B.Sc. in Biology in 2000. He pursued further studies at Tarbiat Modares University, Tehran, completing his M.Sc. in Biochemistry in 2003 and his Ph.D. in 2008. His doctoral research included a significant stint at Utrecht University in the Netherlands, where he honed his expertise in protein engineering.

PROFESSIONAL ENDEAVORS 🏛️

Following his Ph.D., Dr. Asghari joined the University of Guilan in 2009 as an assistant professor, ascending to the role of associate professor in 2017. His academic career took a pivotal turn in 2020 when he joined the Institute of Biochemistry and Biophysics at the University of Tehran. Here, he has been instrumental in advancing research and teaching in the field of novel anticancer peptides. Dr. Asghari’s professional role extends beyond academia as he leads a knowledge-enterprise company focused on peptide-based industrial applications.

CONTRIBUTIONS AND RESEARCH FOCUS 🔬

Dr. Asghari’s research is centered around developing novel peptides and peptidomimetics with potential medical applications. His work includes VEGF-mimicking peptides that interact with key tumor microenvironment receptors and endostatin-derived peptides that inhibit angiogenesis. These peptides are designed to enhance tumor imaging, targeted drug delivery, and the inhibition of pathological angiogenesis, providing Cancer diagnosis innovative solutions for cancer and age-related diseases. His ongoing projects include developing peptide-based technologies for tumor imaging and drug delivery, with a focus on improving therapeutic outcomes and diagnostic precision.

ACCREDITATIONS AND RECOGNITION 🏆

Dr. Asghari holds a US patent for a method of synthesizing antagonist peptides and has published over 80 articles on tumor-targeting peptides. His contributions have been recognized through various awards and fellowships, including the European Association for Cancer Research (EACR) travel fellowship and several industry grants. His editorial roles as Associate Editor for the Iranian Journal of Science and Topic Editor for Cancer diagnosis Frontiers in Oncology further highlight his esteemed position in the scientific community.

IMPACT AND INFLUENCE 🌍

Dr. Asghari’s innovative approach has had a profound impact on cancer research and peptide technology. His work has led to significant advancements in tumor imaging and targeted therapy, influencing both academic research and practical applications. The peptide-based growth supplement for aquaculture developed under his leadership demonstrates his commitment to translating scientific discoveries into real-world Cancer diagnosis solutions, enhancing food security and productivity in Iran.

LEGACY AND FUTURE CONTRIBUTIONS 🔮

Dr. Asghari’s legacy is defined by his pioneering work in peptide science and his contributions to cancer therapy and imaging. His innovative research continues to push the boundaries of biochemistry and biophysics, with ongoing projects aimed at expanding the applications of peptide technology. His role as CEO of a knowledge-enterprise company underscores his dedication to integrating scientific research with industrial practice, promising continued advancements and practical benefits in the future.

NOTABLE PUBLICATIONS

Novel Gd-DTPA-peptide for targeted breast tumor magnetic resonance imaging  2024

Synthesis, Radiolabeling, and Biodistribution Study of a Novel DOTA-Peptide for Targeting  2024

Design, Synthesis, and Functional Studies on Noscapine and Cotarnine Amino Acid Derivatives as Antitumor Agents  2023

Vascular endothelial growth factor antagonist peptides inhibit tumor growth and metastasis in breast 2023

A VEGFB-Based Peptidomimetic Inhibits VEGFR2-Mediated PI3K/Akt/mTOR and PLCγ/ERK Signaling 2023

Dr. WenQing Yang – Translational preclinical modelling for cancer and autoimmune diseases – Industry Leadership Excellence Award

Posted on by sciencefatherLeave a Comment on Dr. WenQing Yang – Translational preclinical modelling for cancer and autoimmune diseases – Industry Leadership Excellence Award

Dr. WenQing Yang - Translational preclinical modelling for cancer and autoimmune diseases - Industry Leadership Excellence Award

ClinBridge Biotechnology Corporation Limited - China

Professional Profile

SCOPUS

ORCID

🎓 EARLY ACADEMIC PURSUITS

WenQing Yang, Ph.D., embarked on a distinguished academic journey that laid the foundation for his influential career in biomedical research. His early education was marked by a profound interest in understanding complex biological systems, which guided him through rigorous academic training. Dr. Yang’s academic pursuits provided him with a robust understanding of animal disease modeling and cancer pharmacology, paving the way for his future contributions in these fields.

💼 PROFESSIONAL ENDEAVORS

With over 30 years of experience, Dr. Yang has made significant strides in drug discovery and development. His professional career began with a focus on early-stage drug discovery, where he demonstrated exceptional skill in advancing drug candidates from discovery to clinical development. Dr. Yang's career spans roles in both large pharmaceutical companies and small biotech firms, showcasing his versatility and leadership. His tenure as Founder and Chief Scientific Officer at Clinbridge Biotech Co. Ltd has been pivotal in establishing the company’s research and discovery infrastructure, driving scientific programs, and fostering global collaborations.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS

Dr. Yang’s research has been instrumental in the areas of cancer pharmacology, immuno-oncology, and autoimmune diseases. His work encompasses a wide range of activities, from animal disease modeling and cancer immunotherapy discovery to novel therapeutic targets validation. Dr. Yang’s expertise in dissecting the tumor micro-environment and validating biomarkers has led to significant advancements in understanding and treating complex diseases. His contributions to translational research have been crucial in bridging the gap between Translational preclinical modelling for cancer and autoimmune diseases preclinical studies and clinical applications.

🏆 ACCOLADES AND RECOGNITION

Throughout his career, Dr. Yang has been recognized for his exceptional contributions to biomedical research and drug discovery. His leadership in advancing over 20 drug candidates to PCC nomination or IND filing, with 15 molecules progressing to clinical trials, highlights his impact on the field. His role in leading translational sciences at Simcere Pharma Group Ltd further solidified his reputation as a leader in drug development and Translational preclinical modelling for cancer and autoimmune diseases translational research.

🌍 IMPACT AND INFLUENCE

Dr. Yang’s influence extends globally, with his research impacting both academic and clinical settings. His efforts in advancing drug discovery and development have led to innovative therapeutic approaches in oncology and immuno-oncology. By establishing and leading scientific programs Translational preclinical modelling for cancer and autoimmune diseases at Clinbridge Biotech and Simcere Pharma, Dr. Yang has played a crucial role in shaping the future of drug discovery and translational medicine, driving forward new treatments and therapeutic strategies.

🏛️ LEGACY AND FUTURE CONTRIBUTIONS

Dr. Yang’s legacy is characterized by his dedication to advancing biomedical research and drug discovery. His work has set new standards in cancer pharmacology, immuno-oncology, and autoimmune diseases. Looking ahead, Dr. Yang is poised to continue his impactful work, focusing on novel therapeutics and innovative research approaches. His commitment to scientific excellence and leadership will undoubtedly inspire future advancements in the field, ensuring that his contributions continue to benefit the biomedical community for years to come.

NOTABLE PUBLICATIONS

A novel form of docetaxel polymeric micelles demonstrates anti-tumor and ascites-inhibitory  2022(2)

Targeting the Homologous Recombination Pathway in Cancer With a Novel Class of RAD51 Inhibitors 2022(4)

Antiangiogenic antibody BD0801 combined with immune checkpoint inhibitors achieves synergistic  2021(10)

Application of magnetic nanoparticles for tumor-targeting hyperthemia 2016(1)

CC-223, a potent and selective inhibitor of mTOR kinase: In vitro and in vivo characterization  2015(48)